Advanced search
Publication Cover
OncoImmunology Volume 10, 2021 - Issue 1
Submit an article Journal homepage
2,052
Views
3
CrossRef citations to date
0
Altmetric
Author’s View

Inhibition of RANK signaling as a potential immunotherapy in breast cancer

C Gómez-Alezaa Oncobell, Bellvitge Biomedical Research Institute, IDIBELL, Barcelona, SpainORCID Iconhttps://orcid.org/0000-0002-4645-5719View further author information
ORCID Icon &
E González-Suáreza Oncobell, Bellvitge Biomedical Research Institute, IDIBELL, Barcelona, Spain;b Molecular Oncology, Spanish National Cancer Research Centre (CNIO), Madrid, SpainCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-0858-8171View further author information
ORCID Icon
Article: 1923156 | Received 21 Apr 2021, Accepted 23 Apr 2021, Published online: 14 May 2021

References

  • González-Suárez E, Sanz-Moreno A. RANK as a therapeutic target in cancer. FEBS J. 2016;283:2018–2. doi:10.1111/febs.13645.
  • Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R, Pinkas J, Branstetter D, Dougall WC. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature. 2010;468:103–107. doi:10.1038/nature09495.
  • Joshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA, Clarke CL, Stingl J, Waterhouse PD, Khokha R. Progesterone induces adult mammary stem cell expansion. Nature. 2010;465:803–807. doi:10.1038/nature09091.
  • Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, Hanada R, Joshi PA, Aliprantis A, Glimcher L, et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature. 2010;468:98–102. doi:10.1038/nature09387.
  • Yoldi G, Pellegrini P, Trinidad EM, Cordero A, Gomez-Miragaya J, Serra-Musach J, Dougall WC, Muñoz P, Pujana M-A, Planelles L, et al. RANK signaling blockade reduces breast cancer recurrence by inducing tumor cell differentiation. Cancer Res. 2016;76:5857–5869. doi:10.1158/0008-5472.CAN-15-2745.
  • Nolan E, Vaillant F, Branstetter D, Pal B, Giner G, Whitehead L, Lok SW, Mann GB, Rohrbach K, Huang L-Y, et al. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. Nat Med. 2016;22:933–939. doi:10.1038/nm.4118.
  • Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T, Daro E, Smith J, Tometsko ME, Maliszewski CR, et al. RANK is essential for osteoclast and lymph node development. Genes Dev. 1999;13:2412–2424. doi:10.1101/gad.13.18.2412.
  • Walsh MC, Choi Y. Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond. Front Immunol. 2014;5:511. doi:10.3389/fimmu.2014.00511.
  • Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997;390:175–179. doi:10.1038/36593.
  • Gatti-Mays ME, Balko JM, Gameiro SR, Bear HD, Prabhakaran S, Fukui J, Disis ML, Nanda R, Gulley JL, Kalinsky K, et al. If we build it they will come: targeting the immune response to breast cancer. npj Breast Cancer. 2019;5:37. doi:10.1038/s41523-019-0133-7.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.